César de Oliviera Lopes Dusilek

César de Oliviera Lopes Dusilek

Auto-generated profile, based on publicly available information

César de Oliviera Lopes Dusilek

Hospital do Rocio, Núcleo de Pesquisa Clínica, Campo Largo, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
LBLívia Pimenta Bonifácio
Lívia Pimenta Bonifácio
EREduardo Ramacciotti
Eduardo Ramacciotti
LALeandro Barile Agati
Leandro Barile Agati
FVFernando Crivelenti Vilar
Fernando Crivelenti Vilar
ASAnna Christina Tojal da Silva
Anna Christina Tojal da Silva
FBFernando Bellissimo-Rodrigues
Fernando Bellissimo-Rodrigues
Cases of coronavirus disease 2019 (COVID-19) requiring hospitalization continue to appear in vulnerable populations, highlighting the importance of novel treatments. The hyperinflammatory response underlies the severity of the disease, and targeting this pathway may be useful. Herein, we tested whether immunomodulation focusing on interleukin (IL)-6, IL-17, and IL-2, could improve the clinical outcomes of patients admitted with COVID-19. This multicenter, open-label, prospective, randomized controlled trial was conducted in Brazil. Sixty hospitalized patients with moderate-to-critical COVID-19 received in addition to standard of care (SOC): IL-17 inhibitor (ixekizumab 80 mg SC/week) 1 dose every 4 weeks; low-dose IL-2 (1.5 million IU per day) for 7 days or until discharge; or indirect IL-6 inhibitor (colchicine) orally (0.5 mg) every 8 hours for 3 days, followed by 4 weeks at 0.5 mg 2x/day; or SOC alone. The primary outcome was accessed in the “per protocol” population as the proportion of patients with clinical improvement, defined as a decrease greater or equal to two points on the World Health Organization’s (WHO) seven-category ordinal scale by day 28. All treatments were safe, and the efficacy outcomes did not differ significantly from those of SOC. Interestingly, in the colchicine group, all participants had an improvement of greater or equal to two points on the WHO seven-category ordinal scale and no deaths or patient deterioration were observed. Ixekizumab, colchicine, and IL-2 were demonstrated to be safe but ineffective for COVID-19 treatment. These results must be interpreted cautiously because of the limited sample size.

29 April 2025 in Cardiology and Therapy
Verified
Journal Article
Open access
PDF file
LGLuís Henrique Wolff Gowdak
Luís Henrique Wolff Gowdak
PDPAULO DOURADO
PAULO DOURADO
DPDalton Bertolim Précoma
Dalton Bertolim Précoma
CDCésar de Oliviera Lopes Dusilek
César de Oliviera Lopes Dusilek
FSFrancisco Maia da Silva
Francisco Maia da Silva
OIon behalf of the V-GOOD Investigators
on behalf of the V-GOOD Investigators
Introduction The V-GOOD study evaluated the effectiveness of trimetazidine modified-release (MR) 80 mg once daily (OD) in patients with chronic coronary syndrome (CCS) who remained symptomatic despite antianginal therapies in routine clinical practice. Methods This prospective, observational study involved 1026 adult outpatients with symptomatic CCS from 70 sites in Brazil who were prescribed trimetazidine MR 80 mg OD plus background antianginal treatment. Data on number of angina attacks, short-acting nitrate consumption, prevalence of angina-free patients, severity of angina, patient-reported daily physical activity impairment, treatment adherence, tolerability, and cardiologist and patient satisfaction were collected at baseline (V1), then at 1 month (V2) and 3 months (V3). Results Following the addition of trimetazidine MR 80 mg OD, the mean ± standard deviation number of angina attacks per week decreased from 3.1 ± 2.8 at V1 to 1.0 ± 2.1 at V2, and 0.7 ± 1.7 at V3, with concurrent reductions in short-acting nitrate consumption, patient-reported daily physical activity impairment and the proportion of patients with limiting angina (Canadian Cardiovascular Society class III or IV), and increases in the proportion of angina-free patients (all p < 0.001 vs. V1). Most cardiologists rated trimetazidine MR 80 mg OD as satisfactory/very satisfactory (90.7% for effectiveness and 94.8% for tolerability); most patients rated the treatment schedule as convenient/very convenient (97.2%) and satisfactory/very satisfactory (97.1%). Treatment was well tolerated. Conclusions These data support the symptomatic benefits and good tolerability associated with adding trimetazidine MR 80 mg OD to other antianginal therapies in patients with persistent symptoms. Graphical abstract available for this article. Trial registration number NCT06464276. Graphical Abstract